Halozyme Therapeutics traded at $44.10 this Wednesday August 10th, increasing $0.77 or 1.78 percent since the previous trading session. Looking back, over the last four weeks, Halozyme Therapeutics gained 11.80 percent. Over the last 12 months, its price rose by 8.22 percent. Looking ahead, we forecast Halozyme Therapeutics to be priced at 43.88 by the end of this quarter and at 40.33 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 16.15 -0.07 -0.43% -11.89%
Agios Pharmaceuticals 28.22 0.85 3.11% -35.70%
Alnylam Pharmaceuticals 232.00 8.63 3.86% 14.37%
Amgen 252.09 3.73 1.50% 10.50%
Amarin 1.53 0.12 8.51% -68.97%
Aptinyx Inc 0.69 0.13 24.22% -71.73%
Baxter International 59.90 0.95 1.61% -19.03%
Cara Therapeutics 12.56 0.75 6.35% -4.27%
Cytokinetics 52.74 0.24 0.46% 62.13%
DBV Technologies 2.71 -0.05 -1.81% -42.95%
Esperion Therapeutics 6.41 -0.02 -0.31% -54.47%
Halozyme Therapeutics 44.10 0.77 1.78% 8.22%
Intercept Pharmaceuticals 16.70 0.04 0.24% 9.36%
Immunogen 5.31 0.04 0.76% -8.92%
Ionis Pharmaceuticals 46.11 1.85 4.18% 20.68%
Intra Cellular Therapies 59.19 2.86 5.08% 102.84%
Jazz Pharmaceuticals 157.43 0.88 0.56% 8.56%
Eli Lilly 304.61 1.59 0.52% 15.34%
MannKind 4.29 0.20 4.89% 7.52%
Minerva Neurosciences 3.42 -0.18 -5.00% 102.37%
Nektar Therapeutics 4.85 0.14 2.97% -66.20%
Pfizer 49.95 0.17 0.34% 7.86%
Peregrine Pharmaceuticals 19.27 1.61 9.12% -17.15%
Rigel Pharmaceuticals 1.51 0.15 11.03% -62.44%
United Therapeutics 221.49 2.32 1.06% 9.53%
Vanda Pharmaceuticals 10.55 0.28 2.73% -34.72%
Intrexon 2.42 0.11 4.76% -60.59%

Indexes Price Day Year
USND 12855 360.88 2.89% -12.94%
US2000 1969 56.36 2.95% -12.49%

Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.